Travel Considerations Specified for Lu-177-DOTATATE Radiation Therapy Patients

April 24, 2020

Reston, VA—A team of researchers and patient advocates has addressed the challenges related to traveling after receiving 177Lu-DOTATATE radiation therapy in a study published in The Journal of Nuclear Medicine. Due to the residual radiation activity of 177Lu-DOTATATE, neuroendocrine tumor patients have experienced travel delays at U.S. ports of entry. It is recommended that patients carry a travel card containing treatment information after each therapy cycle and for an additional three months after therapy has concluded to avoid travel delays.

“Disruption in travel, especially if not anticipated, can be extremely distressing for patients who have enough to deal with already. For many such patients, this travel is meant to take the mind off of their disease. Being stopped at borders is, without a doubt, potentially traumatic,” said Thorvardur R. Halfdanarson, MD, professor of oncology at the Mayo Clinic Cancer Center in Rochester, Minnesota.

Approved by the U.S. Food and Drug Administration (FDA) in 2018, 177Lu-DOTATATE has been used for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors by more than 150 hospitals and medical centers throughout the United States. The radiation from the treatment is not harmful to others, but it can be detected by sensitive radiation detectors at international airports and border crossings and can lead to travel delays. Furthermore, the metastable isotope 177mLu, which is present after treatment with 177Lu-DOTATATE, can be mistaken for plutonium at ports of entry, as plutonium and 177mLu have some similarities in their radiation signatures. This can contribute to additional wait times.

To alleviate potential delays while traveling, the study authors recommend that patients be given a travel card containing the patient’s personal information, type of radiation received, dose of radiation administered and date of administration. The card should also include information about the treating institution and contact information with 24-hour access in case further information is required. In addition, patients should carry a copy of their most recent clinical notes in a single envelope that is easily accessible when going through U.S. border crossings, ports of entry and high-security areas.

According to Halfdanarson, providing education for patients and treating physicians is key. Physicians should advise patients that they may be delayed at various points of travel and that they should allow extra time when traveling, especially when transferring between international and domestic flights. Frequent communication between the FDA, Nuclear Regulatory Commission, Customs and Border Protection (CBP) and researchers should continue in order to keep the staff up to date on the current use of medical isotopes and to help CBP make appropriate radiation-detection equipment choices. Training and improvements in detection technology can help mitigate the travel delays.

“All of the new and exciting developments in nuclear medicine therapies are changing how we practice nuclear medicine and molecular imaging. As more therapies using different radionuclides are brought into clinical practice, this change will become more significant,” noted Ayşe Tuba Kendi, MD, associate professor in the division of nuclear medicine, department of radiology, at the Mayo Clinic in Rochester, Minnesota. “This unique article is a great example of teamwork, connection and communication with patients, colleagues and experts, which are key elements for success of nuclear therapies.”

The authors of “Patient Travel Concerns After Treatment with 177Lu-DOTATATE” include Ayşe Tuba Kendi, Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota; Josh A. Mailman, NorCal CarciNET Community, Oakland, California; Boris G. Naraev, Banner M.D. Anderson Cancer Center, Gilbert, Arizona; David J. Mercer, Los Alamos National Laboratory, Los Alamos, New Mexico; James K. Underwood, Mayo Clinic Radiation Safety, Rochester, Minnesota; and Thorvardur R. Halfdanarson, Mayo Clinic Cancer Center, Rochester, Minnesota.


Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or Current and past issues of The Journal of Nuclear Medicine can be found online at

About the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed close to 10 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit